<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Genomics Division ", fill: "#873260"},
{source: "3: Genomics Division ", target: "3: revenue growth", fill: "#873260"},
{source: "3: revenue growth", target: "3: sustain profitability", fill: "#873260"},
{source: "3: sustain profitability", target: "3: additional customers", fill: "#873260"},
{source: "3: Genomics Division ", target: "13: future growth", fill: "#d6cadd"},
{source: "13: future growth", target: "13: also dependent upon continuing", fill: "#d6cadd"},
{source: "13: also dependent upon continuing", target: "13: potential customer base through", fill: "#d6cadd"},
{source: "13: potential customer base through", target: "13: existing services", fill: "#d6cadd"},
{source: "13: existing services", target: "13: growing sales", fill: "#d6cadd"},
{source: "13: growing sales", target: "13: toxicogenomics services software", fill: "#d6cadd"},
{source: "13: toxicogenomics services software", target: "13: microarray data generation", fill: "#d6cadd"},
{source: "13: microarray data generation", target: "13: professional", fill: "#d6cadd"},
{source: "13: professional", target: "13: solutions eg", fill: "#d6cadd"},
{source: "13: future growth", target: "20: Approximately ", fill: "#a67b5b"},
{source: "20: Approximately ", target: "20: three years certain", fill: "#a67b5b"},
{source: "20: three years certain", target: "20: microarray", fill: "#a67b5b"},
{source: "20: microarray", target: "20: Affymetrix ", fill: "#a67b5b"},
{source: "20: Affymetrix ", target: "20: necessary", fill: "#a67b5b"},
{source: "20: necessary", target: "20: databases which", fill: "#a67b5b"},
{source: "20: databases which", target: "20: timeconsuming", fill: "#a67b5b"},
{source: "20: timeconsuming", target: "20: significant expense", fill: "#a67b5b"},
{source: "20: Approximately ", target: "30: against existing", fill: "#00416a"},
{source: "30: against existing", target: "30: future technologies", fill: "#00416a"},
{source: "30: future technologies", target: "30: technologies", fill: "#00416a"},
{source: "30: technologies", target: "30: demonstrate", fill: "#00416a"},
{source: "30: demonstrate", target: "30: existing customers", fill: "#00416a"},
{source: "30: existing customers", target: "30: capabilities", fill: "#00416a"},
{source: "30: capabilities", target: "30: Genomics Division ", fill: "#00416a"},
{source: "30: Genomics Division ", target: "30: specifically", fill: "#00416a"},
{source: "30: specifically", target: "30: the BioExpress System and ToxExpress System ", fill: "#00416a"},
{source: "30: the BioExpress System and ToxExpress System ", target: "30: databases", fill: "#00416a"},
{source: "30: databases", target: "30: competing technologies andor", fill: "#00416a"},
{source: "30: against existing", target: "52: Risks Related ", fill: "#90ee90"},
{source: "52: Risks Related ", target: "52: Preclinical Division ", fill: "#90ee90"},
{source: "52: Preclinical Division ", target: "52: operations", fill: "#90ee90"},
{source: "52: operations", target: "52: adversely", fill: "#90ee90"},
{source: "52: adversely", target: "52: additional contracts", fill: "#90ee90"},
{source: "52: additional contracts", target: "52: generate greater", fill: "#90ee90"},
{source: "52: generate greater", target: "52: revenue from existing", fill: "#90ee90"},
{source: "52: revenue from existing", target: "52: new customers", fill: "#90ee90"},
{source: "52: Risks Related ", target: "54: could prevent us from", fill: "#db7093"},
{source: "54: could prevent us from", target: "54: adequate numbers", fill: "#db7093"},
{source: "54: adequate numbers", target: "54: appropriate types", fill: "#db7093"},
{source: "54: appropriate types", target: "54: studies on", fill: "#db7093"},
{source: "54: studies on", target: "54: timely basis", fill: "#db7093"},
{source: "54: timely basis", target: "54: factors set forth", fill: "#db7093"},
{source: "54: factors set forth", target: "54: Risks Related ", fill: "#db7093"},
{source: "54: Risks Related ", target: "54: Preclinical Division ", fill: "#db7093"},
{source: "54: Preclinical Division ", target: "54: competitive", fill: "#db7093"},
{source: "54: competitive", target: "54: competitors", fill: "#db7093"},
{source: "54: competitors", target: "54: utilization", fill: "#db7093"},
{source: "54: utilization", target: "54: capacity", fill: "#db7093"},
{source: "54: capacity", target: "54: the FDA Letter ", fill: "#db7093"},
{source: "54: the FDA Letter ", target: "54: will continue", fill: "#db7093"},
{source: "54: will continue", target: "54: negative impact on", fill: "#db7093"},
{source: "54: negative impact on", target: "54: quality studies", fill: "#db7093"},
{source: "54: could prevent us from", target: "89: Terminations ", fill: "#fff600"},
{source: "89: Terminations ", target: "89: reductions may", fill: "#fff600"},
{source: "89: reductions may", target: "89: study services lack", fill: "#fff600"},
{source: "89: study services lack", target: "89: availability", fill: "#fff600"},
{source: "89: availability", target: "89: development", fill: "#fff600"},
{source: "89: development", target: "89: test compound", fill: "#fff600"},
{source: "89: test compound", target: "89: particular study", fill: "#fff600"},
{source: "89: particular study", target: "89: duties under", fill: "#fff600"},
{source: "89: duties under", target: "89: study services contract", fill: "#fff600"},
{source: "89: Terminations ", target: "START_HERE", fill: "#fff600"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Negotiation</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Censorship</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/VISTA_(comparative_genomics)">VISTA (comparative genomics)</a></td>
      <td>VISTA is a collection of databases, tools, and servers that permit extensive comparative genomics analyses.\n\n\n== Background ==\nThe VISTA family of tools is developed and hosted at the Genomics Division of Lawrence Berkeley National Laboratory.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Neogen">Neogen</a></td>
      <td>The Neogene ( NEE-ə-jeen), informally Upper Tertiary or Late Tertiary, is a geologic period and system that spans 20.45 million years from the end of the Paleogene Period 23.03 million years ago (Mya) to the beginning of the present Quaternary Period 2.58 Mya. The Neogene is sub-divided into two epochs, the earlier Miocene and the later Pliocene.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Metagenomics">Metagenomics</a></td>
      <td>Metagenomics is the study of genetic material recovered directly from environmental samples. The broad field may also be referred to as environmental genomics, ecogenomics or community genomics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Biosearch_Technologies">Biosearch Technologies</a></td>
      <td>LGC, Biosearch Technologies, is a biotechnology company headquartered in Hoddesdon, UK. Formerly known as LGC Genomics, which acquired Biosearch Technologies, Inc. - located in Petaluma, CA in 2015 (a vertically integrated company that specializes in custom synthesized oligonucleotides for qPCR, cGMP oligos for molecular diagnostics, and DNA/RNA synthesis reagents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Complete_Genomics">Complete Genomics</a></td>
      <td>Complete Genomics is a life sciences company that has developed and commercialized a DNA sequencing platform for human genome sequencing and analysis. This solution combines the company's proprietary human genome sequencing technology with its informatics and data management software to provide finished variant reports and assemblies at Complete Genomics’ own commercial genome center in Mountain View, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genomic_imprinting">Genomic imprinting</a></td>
      <td>Genomic imprinting is an epigenetic phenomenon that causes genes to be expressed or not, depending on whether they are inherited from the mother or the father. Genes can also be partially imprinted.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Genomic_organization">Genomic organization</a></td>
      <td>The hereditary material i.e. DNA (deoxyribonucleic acid) of an organism is composed of a sequence of four nucleotides in a specific pattern, which encode information as a function of their order.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cell_division">Cell division</a></td>
      <td>Cell division is the process by which a parent cell divides, when a mother cell divides into two or more daughter cells. Cell division usually occurs as part of a larger cell cycle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/LGC_Ltd">LGC Ltd</a></td>
      <td>LGC Group, formerly the Laboratory of the Government Chemist, is an international life sciences measurement and tools company, which also provides the role and duties of the UK Government Chemist, a statutory role and adviser to the government. LGC also hosts the UK's National Measurement Laboratory (NML) for chemical and bio-measurement, which performs measurements for diagnostics, advanced therapeutics, safety and security, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/DNA_microarray">DNA microarray</a></td>
      <td>A DNA microarray (also commonly known as DNA chip or biochip) is a collection of microscopic DNA spots attached to a solid surface. Scientists use DNA microarrays to measure the expression levels of large numbers of genes simultaneously or to genotype multiple regions of a genome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Palantir_Technologies">Palantir Technologies</a></td>
      <td>Palantir Technologies is a public American software company that specializes in big data analytics. Headquartered in Denver, Colorado, it was founded by Peter Thiel, Nathan Gettings, Joe Lonsdale, Stephen Cohen, and Alex Karp in 2003.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bruker">Bruker</a></td>
      <td>Brucker is a surname, and may refer to:</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fırat_University_Faculty_of_Veterinary_Medicine">Fırat University Faculty of Veterinary Medicine</a></td>
      <td>Fırat University Faculty of Veterinary Medicine is among the few faculties that have achieved full accreditation by EAEVE in Turkey. Fırat University Faculty of Veterinary Medicine was created in 1970.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Doctor_of_Medicine">Doctor of Medicine</a></td>
      <td>Doctor of Medicine (abbreviated M.D., from the Latin Medicinae Doctor) is a medical degree, the meaning of which varies between different jurisdictions. In the United States, and some other countries, the M.D. denotes a professional graduate degree.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/School_of_Medicine,_University_of_Patras">School of Medicine, University of Patras</a></td>
      <td>School of Medicine is one of the two departments of the School of Health Sciencess, University of Patras.\nThe School of Medicine of the University of Patras was founded in 1977 and admitted its first students in October of the same academic year.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Division_of_Acquired_Immunodeficiency_Syndrome">Division of Acquired Immunodeficiency Syndrome</a></td>
      <td>The Division of Acquired Immunodeficiency Syndrome (DAIDS) is a division of the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health. It was formed in 1986 as a part of the initiative to address the national research needs created by the advent and spread of the HIV/AIDS epidemic.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Creighton_University_School_of_Medicine">Creighton University School of Medicine</a></td>
      <td>The Creighton University School of Medicine is the graduate medical school at Creighton University in Omaha, Nebraska, United States, and grants the Doctor of Medicine (MD) degree. It was founded in 1892.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Charles_River_Laboratories">Charles River Laboratories</a></td>
      <td>Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry (for example, contract research organization services) and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Poxviridae">Poxviridae</a></td>
      <td>Poxviridae is a family of viruses. Vertebrates, and arthropods serve as natural hosts.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Labcorp_Drug_Development">Labcorp Drug Development</a></td>
      <td>Labcorp Drug Development is a contract research organization (CRO) headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is part of Labcorp, which employs more than 70,000 people worldwide.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_studies">Development studies</a></td>
      <td>Development studies is an interdisciplinary branch of social science. Development studies is offered as a specialized master's degree in a number of reputed universities around the world, such as the University of Cambridge, the London School of Economics and Political Science, King’s College London, the Institute of Development Studies at the University of Sussex, Oxford University, Harvard University, Balsillie School of International Affairs, Graduate Institute Geneva, Indian Institute of Technology Madras, SOAS London, Tata Institute of Social Sciences and University of Warwick, and less commonly, as an undergraduate degree, such as at the University of Sussex, University of Guelph, University of Toronto and McGill University.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>GENE LOGIC INC      ITEM 1A RISK FACTORS     We operate in a rapidly changing <font color="blue">environment</font> that involves a number of     risks, some of which are beyond our control</td>
    </tr>
    <tr>
      <td>Set forth below are risks and     <font color="blue">uncertainties</font> we have identified as material that could cause actual results     to <font color="blue">differ <font color="blue">materially</font> from</font> the results contemplated by the forward-looking     <font color="blue">statements contained</font> in this Form 10-K and that could have material adverse     <font color="blue">effects on</font> our business, results of <font color="blue">operations</font>, <font color="blue">financial condition</font> and cash     flows</td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to Our <font color="blue">Genomics Division </font>    To  generate  <font color="blue">revenue growth</font> and <font color="blue">sustain <font color="blue">profitability</font></font>, we must retain     existing and obtain <font color="blue"><font color="blue">additional</font> customers</font> for our <font color="blue">Genomics Division </font>and     develop new and improved services</td>
    </tr>
    <tr>
      <td>Our <font color="blue">strategy depends</font>, in part, <font color="blue">on continued growth</font> in <font color="blue">revenue from</font> our     Genomics  Division</td>
    </tr>
    <tr>
      <td>To  achieve  <font color="blue">such growth</font>, we <font color="blue">must extend existing</font>     <font color="blue"><font color="blue">subscription</font>s</font> and expand the scope and <font color="blue">revenue potential</font> of <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with</font>     <font color="blue">existing customers</font> and develop <font color="blue">new customers</font></td>
    </tr>
    <tr>
      <td>Each of the <font color="blue">subscription</font>     <font color="blue"><font color="blue">agreement</font>s</font>  that we have with our <font color="blue">Genomics Division </font>customers is for a     <font color="blue">specific term</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreement</font>s</font> may be <font color="blue">terminated by either party</font> in the     event  of  breach or <font color="blue">bankruptcy</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">subscription</font> <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with</font> major     customers  are  terminated or expire and are not extended, or existing     <font color="blue">customers fail</font> to <font color="blue">buy <font color="blue">additional</font> services</font>, or if we fail to <font color="blue">enter into</font>     <font color="blue">subscription</font> <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with</font> <font color="blue">new customers</font>, our business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>In 2006, <font color="blue">subscription</font> <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with</font> five <font color="blue">customers will</font> expire by their     terms  and two <font color="blue"><font color="blue">agreement</font>s</font> may terminate at the customer’s election</td>
    </tr>
    <tr>
      <td>We     received notice <font color="blue">from one such customer</font> of its election to terminate its     <font color="blue">agreement</font> in 2006 and the other customer did not elect to exercise its right     to terminate its <font color="blue">agreement</font> early</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreement</font>s</font> accounted for 20prca of our     total 2005 revenue and 28prca of our 2005 <font color="blue">Genomics Division </font>revenue</td>
    </tr>
    <tr>
      <td>There is     no assurance that the remaining <font color="blue"><font color="blue">agreement</font>s</font> scheduled to expire will be     extended or that any <font color="blue"><font color="blue">agreement</font>s</font> resulting from our <font color="blue"><font color="blue">discussions with</font> such</font>     <font color="blue">customers will</font> be <font color="blue">on terms comparable</font> to, or as favorable to us as, the     existing <font color="blue">subscription</font> <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future growth</font> is <font color="blue">also dependent upon continuing</font> to expand our services     offering and <font color="blue">potential customer base through</font> developing new and improving     <font color="blue">existing services</font> and <font color="blue">growing sales</font> of our <font color="blue">toxicogenomics</font> services, software     tools,  <font color="blue"><font color="blue">microarray</font> data <font color="blue">generation</font></font> and analysis and other <font color="blue">professional</font>     services and solutions (eg, ASCENTA System and ToxShield)</td>
    </tr>
    <tr>
      <td>If we fail to achieve any of these goals, our <font color="blue">Genomics Division </font>segment     could experience <font color="blue">financial losses</font> and our entire business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>Our genomics and <font color="blue"><font color="blue">toxicogenomics</font> <font color="blue">databases</font></font> require <font color="blue">continual upgrading</font> and     expansion, which may be <font color="blue">difficult</font> or expensive</td>
    </tr>
    <tr>
      <td>To continue to build our Genomics Division, we require <font color="blue">timely access</font> to     normal  and <font color="blue">diseased human</font> and <font color="blue">animal <font color="blue">tissue samples</font></font>, other biological     materials and related clinical and other information</td>
    </tr>
    <tr>
      <td>Specific tissue and     <font color="blue">blood samples</font> that we believe will enhance the content of our <font color="blue"><font color="blue">databases</font> may</font>     be <font color="blue">difficult</font> to obtain or may not be <font color="blue">available on terms</font> acceptable to us</td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">government</font> regulation in the <font color="blue">United States </font>and foreign countries     could restrict access to, or use of, human and other <font color="blue">tissue samples</font> and     related data</td>
    </tr>
    <tr>
      <td>If we <font color="blue">lose access</font> to <font color="blue">sufficient numbers</font> or sources of tissue     samples or if <font color="blue">tighter restrictions</font> are <font color="blue">imposed on</font> our use of the information     generated from <font color="blue">tissue samples</font> and related data, our <font color="blue">Genomics Division </font>may     suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>every two to three years, certain changes in the <font color="blue">microarray</font>     platforms that we use from <font color="blue"><font color="blue">Affymetrix</font> </font>may be <font color="blue">necessary</font> and require us to     upgrade the content of our <font color="blue">databases</font>, which is time-consuming and requires     <font color="blue"><font color="blue">significant</font> expense</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">upgrades could</font> be more frequent, costly or     <font color="blue">difficult</font> or some <font color="blue">customers may</font> want the <font color="blue">databases</font> to be <font color="blue">reproduced on</font> a     <font color="blue">different</font> <font color="blue"><font color="blue">technology</font> platform</font>, which would be costly to implement</td>
    </tr>
    <tr>
      <td>In 2005,     we completed the upgrade of our <font color="blue"><font color="blue">BioExpress </font>System </font><font color="blue">database using</font> the latest     human <font color="blue">GeneChip </font><font color="blue">microarray</font>s from <font color="blue">Affymetrix</font></td>
    </tr>
    <tr>
      <td>In 2006, we expect to upgrade     our <font color="blue">ToxExpress System </font><font color="blue">database using</font> <font color="blue">GeneChip </font><font color="blue">microarray</font>s from <font color="blue">Affymetrix</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">genomics industry</font> is <font color="blue">competitive</font> and <font color="blue">evolving rapidly</font>, and our Genomics     Division <font color="blue">may become obsolete</font> or fail to be <font color="blue">sufficiently useful</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>exists <font color="blue">among entities attempting</font> to identify <font color="blue">genes associated</font>     with specific diseases, conduct toxicity testing of compounds and develop     products and <font color="blue">services based on</font> these <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">Genomics Division </font>    <font color="blue">directly competes</font> in these <font color="blue">areas with <font color="blue">pharmaceutical</font></font> and <font color="blue">bio<font color="blue">technology</font></font>     companies  and other <font color="blue">companies providing services</font> to these <font color="blue">industries</font>,     academic and non-profit <font color="blue">institutions</font> and <font color="blue">government</font> or other <font color="blue">publicly funded</font>     agencies, both in the <font color="blue">United States </font>and abroad</td>
    </tr>
    <tr>
      <td>We are aware that these     entities are using a variety of <font color="blue">gene expression</font> analysis methodologies,     including the use of <font color="blue">microarray</font>s, to attempt to identify disease-related     genes and to develop and make available <font color="blue">databases</font> of <font color="blue">gene expression</font> and     <font color="blue"><font color="blue">toxicogenomics</font> data</font></td>
    </tr>
    <tr>
      <td>In some cases, such <font color="blue">databases</font> and other <font color="blue">genomic data</font>     may be publicly available, but to our <font color="blue">knowledge none</font> of such <font color="blue">databases</font> are     comparable in scope or utility to ours</td>
    </tr>
    <tr>
      <td>In addition, certain <font color="blue">pharmaceutical</font>     companies are developing in-house genomic research programs</td>
    </tr>
    <tr>
      <td>To compete     <font color="blue">against existing</font> and <font color="blue">future <font color="blue">technologies</font></font>, we will need to continue to be     able  to  <font color="blue">demonstrate</font>  to  potential  and  <font color="blue">existing customers</font> that the     <font color="blue">technologies</font>  and  <font color="blue">capabilities</font>  supporting our <font color="blue">Genomics Division </font>and,     <font color="blue">specifically</font>, the <font color="blue"><font color="blue">BioExpress </font>System </font>and <font color="blue">ToxExpress System </font><font color="blue">databases</font>, are     superior  to competing <font color="blue">technologies</font> and/or other <font color="blue">gene expression</font>-based     resources</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________           Our <font color="blue">Genomics Division </font>could become less <font color="blue">competitive</font> if we are not able to     make the <font color="blue">enhancements</font> to our <font color="blue">technology</font> <font color="blue">necessary</font> to <font color="blue">compete <font color="blue">successfully</font></font>     with newly emerging <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The roles of genes in <font color="blue">human biology</font> and     pathology are still being discovered</td>
    </tr>
    <tr>
      <td>Few <font color="blue"><font color="blue">therapeutic</font> products based on gene</font>     <font color="blue">discoveries</font> have <font color="blue">been commercialized</font> to date</td>
    </tr>
    <tr>
      <td>If our <font color="blue">customers no longer</font>     find genomics and/or <font color="blue">toxicogenomics</font> information useful or such information     <font color="blue">becomes obsolete as</font> a <font color="blue">viable drug discovery</font> and <font color="blue"><font color="blue">development</font> resource</font>, our     existing  and  potential <font color="blue">customers may</font> lose confidence in our Genomics     Division and our business may suffer</td>
    </tr>
    <tr>
      <td>The  sales  cycle  for  our <font color="blue">Genomics Division </font>is lengthy; we may spend     considerable <font color="blue">resources on unsuccessful <font color="blue">sales efforts</font></font> or may not be able to     complete <font color="blue">deals on</font> the schedule we anticipate</td>
    </tr>
    <tr>
      <td>The  sales  cycle  for  multi-year <font color="blue"><font color="blue">subscription</font>s</font> to our <font color="blue">BioExpress </font>and     ToxExpress  System <font color="blue">databases</font> is estimated at nine to 15 months, and in     certain  <font color="blue">circumstances</font>  could be longer</td>
    </tr>
    <tr>
      <td>The <font color="blue">sales cycle</font> for our other     services, including <font color="blue">toxicogenomics</font> reports, <font color="blue"><font color="blue">microarray</font> data <font color="blue">generation</font></font> and     analysis and other <font color="blue">professional</font> services and solutions, may not be as long     but is still a matter of <font color="blue">at least several months</font></td>
    </tr>
    <tr>
      <td>The lengthy <font color="blue">sales cycle</font> is     caused by a number of factors, including our need to educate our existing     and  potential  customers  and  sell  the  benefits of the services of     our <font color="blue">Genomics Division </font>to a variety of <font color="blue">groups within such companies</font></td>
    </tr>
    <tr>
      <td>In     addition, each <font color="blue">agreement</font> may involve the <font color="blue">negotiation</font> of <font color="blue">unique terms</font></td>
    </tr>
    <tr>
      <td>We may     expend  substantial  effort  with  no assurance that a new or extended     <font color="blue">subscription</font>  or  other  <font color="blue">agreement</font>  will  result</td>
    </tr>
    <tr>
      <td>Actual and proposed     <font color="blue">consolidations</font> of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies have affected,     and  may in the <font color="blue">future affect</font>, the timing and progress of our Genomics     Division <font color="blue">sales efforts</font></td>
    </tr>
    <tr>
      <td>Accordingly, our results <font color="blue">will fluctuate</font> because it     is  not  always  possible  to  <font color="blue">effectively</font>  time the <font color="blue">initiation</font> of new     <font color="blue">subscription</font> <font color="blue"><font color="blue">agreement</font>s</font> or <font color="blue">extensions</font> of existing <font color="blue">subscription</font> <font color="blue"><font color="blue">agreement</font>s</font>,     or  predict  the  timing  of any potential resulting <font color="blue">revenue from</font> such     <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>We rely on <font color="blue">microarray</font>s and other <font color="blue">products supplied by</font> <font color="blue"><font color="blue">Affymetrix</font> </font>to build     the underlying genomics and <font color="blue"><font color="blue">toxicogenomics</font> data</font> of our <font color="blue">databases</font> and to     provide our <font color="blue"><font color="blue">microarray</font> data <font color="blue">generation</font></font> and <font color="blue">analysis services</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">continuing ability</font> to build and update the <font color="blue">gene expression</font> data that are     the foundation of our <font color="blue">databases</font> depends in part on the ability of <font color="blue"><font color="blue">Affymetrix</font> </font>    to <font color="blue">supply us with</font> adequate quantities of high quality <font color="blue">microarray</font>s and other     products  and  to  make <font color="blue">available licenses</font> of <font color="blue">technologies</font> to use such     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on</font> <font color="blue"><font color="blue">Affymetrix</font> </font><font color="blue">microarray</font>s to provide our <font color="blue">microarray</font>     data  <font color="blue">generation</font>  and <font color="blue">analysis services</font> and on a new line of SNP-based     <font color="blue">microarray</font>s  to provide our <font color="blue">recently launched</font> SNP <font color="blue">genotyping services</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Affymetrix</font> </font>provides us with <font color="blue">microarray</font>s, reagents, instrumentation and     <font color="blue">software under</font> an <font color="blue">agreement</font> that expires <font color="blue">December </font>31, 2006</td>
    </tr>
    <tr>
      <td>There is no     assurance that we can renew that <font color="blue">agreement</font> <font color="blue">on terms comparable</font> to, or as     favorable to us as, the current <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>That <font color="blue">agreement</font> is <font color="blue">also terminable</font>     if we breach the <font color="blue">agreement</font> and fail to cure any <font color="blue">breach within</font> the applicable     <font color="blue">cure period</font></td>
    </tr>
    <tr>
      <td>If <font color="blue"><font color="blue">Affymetrix</font> </font>is unable or unwilling to <font color="blue">supply us with</font> the     products and licenses we require on acceptable terms or if the <font color="blue">microarray</font>s     are  unavailable  or  defective  or <font color="blue">otherwise unreliable</font>, we may incur     <font color="blue"><font color="blue">additional</font> database production costs</font> and we may need to obtain <font color="blue">alternative</font>     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Alternative </font><font color="blue">technologies</font> may not be available to us, or may     only be available to <font color="blue">us on unfavorable terms</font></td>
    </tr>
    <tr>
      <td><font color="blue">Restricted </font>or curtailed access     to such products could cause our <font color="blue">Genomics Division </font>to suffer by preventing     or delaying our ability to provide our services or increasing the cost to     generate <font color="blue">additional</font> content for our <font color="blue">databases</font>, as well as causing us to be     delayed or unable to meet content update <font color="blue">obligations</font> under existing Genomics     Division <font color="blue">subscription</font> <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Risks Related </font>to our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>     The results of <font color="blue">operations</font> of our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>will be <font color="blue">adversely</font>     affected  if we cannot obtain <font color="blue">additional</font> contracts to <font color="blue">generate greater</font>     <font color="blue">revenue from</font> existing and <font color="blue">new customers</font></td>
    </tr>
    <tr>
      <td>To <font color="blue">reduce losses</font> and achieve <font color="blue">profitability</font> in our <font color="blue"><font color="blue">Preclinical </font>Division</font>, we     must  obtain contracts to perform studies in order to <font color="blue">generate greater</font>     <font color="blue">revenue from</font> existing and <font color="blue">new customers</font> and we must obtain the types of     studies  that  can allow us to <font color="blue">optimally use</font> the <font color="blue">capacity</font> of our study     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Factors that <font color="blue">could prevent us from</font> obtaining <font color="blue">adequate numbers</font>,     or <font color="blue">appropriate types</font>, of contracts for <font color="blue">studies on</font> a <font color="blue">timely basis</font> include the     <font color="blue">factors set forth</font> in “<font color="blue">Risks Related </font>to our <font color="blue"><font color="blue">Preclinical </font>Division</font>” and whether     we can provide <font color="blue">competitive</font> pricing vis-a-vis our <font color="blue">competitors</font> whose fixed     cost structures are lower because of higher order volume and higher and     better <font color="blue">utilization</font> of <font color="blue">capacity</font>, and whether <font color="blue">the <font color="blue">FDA Letter </font></font><font color="blue">will continue</font> to     have a <font color="blue">negative impact on</font> our reputation for <font color="blue">quality studies</font></td>
    </tr>
    <tr>
      <td>In addition,     demand by <font color="blue">bio<font color="blue">technology</font></font> and <font color="blue">pharmaceutical</font> companies for in-life animal     studies to test the safety of their <font color="blue">candidate compounds</font> can <font color="blue">fluctuate based</font>     on  internal  <font color="blue"><font color="blue">development</font> pipeline issues</font>, including whether they have     <font color="blue"><font color="blue">candidates</font> ready</font> for such pre-IND studies and <font color="blue">internal choices</font> regarding     <font color="blue">resource allocation</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________           Failure to grow our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>or the absence of <font color="blue">viable strategic</font>     <font color="blue">alternative</font>s for this business could result in continuing material losses</td>
    </tr>
    <tr>
      <td>Our  goal for our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>is to improve its financial and     <font color="blue">operational performance</font></td>
    </tr>
    <tr>
      <td>If we continue to experience <font color="blue">suboptimal demand</font> for     our services, to experience under<font color="blue">utilization</font> of our <font color="blue">capacity</font> and to realize     ongoing  losses for this division and if we are unable to identify and     implement  acceptable  strategic  <font color="blue">alternative</font>s  for  the business, the     <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>could cause us to continue to experience material     losses</td>
    </tr>
    <tr>
      <td>Failure to provide <font color="blue">quality studies</font> could result in a loss of or <font color="blue">inability</font> to     obtain <font color="blue">additional</font> business for our <font color="blue"><font color="blue">Preclinical </font>Division</font></td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">provide services with</font> a level of quality acceptable to our     customers  (eg, in <font color="blue">compliance with agreed study protocols</font>, operating     procedures,  <font color="blue">regulatory</font>  requirements, industry standards and customer     <font color="blue">expectations</font>), we may be required to repeat the study at our expense, or     <font color="blue">refund amounts paid</font> to us for the study, and we may experience an adverse     effect on our reputation and lose business</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to <font color="blue">comply with</font> existing <font color="blue">regulations</font> could result in a loss of     revenue or <font color="blue">increased costs from</font> our <font color="blue"><font color="blue">Preclinical </font>Division</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>is subject to extensive regulation and we are     subject  to  periodic  audit for compliance by <font color="blue">regulatory</font> authorities,     including  the <font color="blue">FDA and the DEA Any </font><font color="blue">failure on</font> our part to <font color="blue">comply with</font>     applicable <font color="blue">regulations</font> could result in the <font color="blue">termination</font> of <font color="blue">ongoing studies</font> or     the <font color="blue">disqualification</font> of data for submission to <font color="blue">regulatory</font> authorities or     other <font color="blue">regulatory</font> action</td>
    </tr>
    <tr>
      <td>If this were to happen, we <font color="blue">could incur</font> <font color="blue">additional</font>     <font color="blue">compliance costs</font> or be subject to <font color="blue">additional</font> <font color="blue">regulatory</font> restrictions, we     could be <font color="blue">contractually</font> required to repeat a study at no further cost to our     customer or refund the cost of the study and <font color="blue">customers might choose</font> not to     <font color="blue">enter into</font> or to <font color="blue">renew contracts</font> for our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>in the future</td>
    </tr>
    <tr>
      <td>We are <font color="blue">also <font color="blue">accredited</font> by</font> an <font color="blue">industry approval</font> group named The Association     for Assessment and Accreditation of Laboratory Animal Care International,     <font color="blue">commonly referred</font> to as “AAALAC”</td>
    </tr>
    <tr>
      <td>AAALAC is a <font color="blue">private nonprofit <font color="blue">organization</font></font>     that promotes the <font color="blue">humane treatment</font> of animals in <font color="blue">science through</font> a voluntary     <font color="blue"><font color="blue">accreditation</font> program</font></td>
    </tr>
    <tr>
      <td>Generally, our <font color="blue">customers insist</font> that their vendors be     AAALAC  <font color="blue">accredited</font>  and,  if we were to fail an inspection or lose our     <font color="blue">accreditation</font>, our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>would be <font color="blue">severely impacted</font></td>
    </tr>
    <tr>
      <td>In     addition, our use of animals for our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>is <font color="blue">also regulated</font>     by the <font color="blue">United States </font>Department of Agriculture</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>is subject to <font color="blue">periodic inspection by</font> the FDA As a     result of an inspection in October 2003, we received an <font color="blue">FDA Warning Letter     </font>(the  “FDA Letter”) in February 2005</td>
    </tr>
    <tr>
      <td><font color="blue">The <font color="blue">FDA Letter </font></font><font color="blue">focused on issues</font>     related to <font color="blue">two preclinical studies conducted</font> in 2001 and 2002 by TherImmune     Research Corporation, prior to its <font color="blue"><font color="blue">acquisition</font> by us</font> in 2003</td>
    </tr>
    <tr>
      <td>The issues     related to how the studies were conducted and to <font color="blue">certain recordkeeping</font>     procedures</td>
    </tr>
    <tr>
      <td>We worked <font color="blue">cooperatively with</font> the <font color="blue">product sponsors</font> for the two     studies to address the <font color="blue">issues raised by</font> the FDA Letter</td>
    </tr>
    <tr>
      <td>We submitted our     response to the FDA, <font color="blue">addressing each</font> of the <font color="blue">violations cited</font> in the FDA     Letter  and  identifying corrective actions we have taken, for further     <font color="blue">consideration</font> by <font color="blue">the FDA Although </font>we do not believe any <font color="blue">further action</font> by     the FDA with regard to this report is likely, there can be no assurance that     the  FDA  will not take <font color="blue">further action</font></td>
    </tr>
    <tr>
      <td><font color="blue">While the Company </font>is unable to     quantify the impact of the FDA Letter, <font color="blue">based on <font color="blue">discussions with</font> current</font> and     <font color="blue">prospective customers</font>, <font color="blue">the <font color="blue">FDA Letter </font></font>has had a negative effect on the     Company’s customers’ perception regarding the Company’s ability to provide     <font color="blue">preclinical contract research services</font></td>
    </tr>
    <tr>
      <td>The FDA is required to inspect our <font color="blue">facilities</font> every two years</td>
    </tr>
    <tr>
      <td><font color="blue">In August     </font>2005,  the  FDA  conducted  a <font color="blue">new inspection</font></td>
    </tr>
    <tr>
      <td>At the <font color="blue">conclusion</font> of the     inspection, they noted four <font color="blue">observations</font>, three of which also related to     <font color="blue">studies done prior</font> to the <font color="blue">acquisition</font> of TherImmune by us and one of which     related to <font color="blue">services provided by</font> a <font color="blue">third party subcontractor</font></td>
    </tr>
    <tr>
      <td>The inspection     did not note any <font color="blue">continuation</font> or recurrence of <font color="blue">discrepancies</font> identified in     the FDA Letter</td>
    </tr>
    <tr>
      <td>We have responded to the FDA <font color="blue">indicating how</font> we were going to     respond to those <font color="blue">observations</font> and improve our processes to make sure those     issues relating to the noted <font color="blue">observations</font> did not recur and <font color="blue">subsequently</font>     reported that we had <font color="blue">taken corrective actions</font> and implemented changes to     prevent any recurrence of the noted <font color="blue">observations</font></td>
    </tr>
    <tr>
      <td>Although we do not believe     any <font color="blue">further action</font> by the FDA with regard to this report is likely, there is     no assurance that the FDA will not take <font color="blue">further action</font></td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________           <font color="blue">Continuing </font><font color="blue">negative performance</font> of our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font><font color="blue">could affect</font> the     value of goodwill and creates risk to our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In  2003,  we  recorded  goodwill  of dlra43dtta0 million as a result of the     <font color="blue">acquisition</font>  of  TherImmune</td>
    </tr>
    <tr>
      <td>(now  Gene  Logic Laboratories Inc, our     <font color="blue"><font color="blue">Preclinical </font>Division</font>)</td>
    </tr>
    <tr>
      <td>Under Statement of Financial Accounting Standards Nodtta     142, “Goodwill and Other Intangible Assets”, we are required to perform an     annual  <font color="blue">impairment</font>  test  of our goodwill and are required to test for     <font color="blue">impairment</font> whenever we have an <font color="blue">indication</font> that <font color="blue">impairment</font> may exist</td>
    </tr>
    <tr>
      <td>During     September  2005, we determined that the carrying value of the goodwill     <font color="blue">associated with</font> our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>was likely impaired, due to lower     than expected performance, including lower than anticipated revenue and     declining gross margins and, in the <font color="blue">fourth quarter</font> of 2005, we recorded a     non-cash expense of dlra32dtta8 million representing the implied <font color="blue">impairment</font> of     goodwill</td>
    </tr>
    <tr>
      <td>Our estimates for <font color="blue">future periods</font> of the <font color="blue">net cash flows may</font> change     <font color="blue">as market <font color="blue">conditions</font></font> and <font color="blue">circumstances</font> dictate</td>
    </tr>
    <tr>
      <td>Future <font color="blue">impairment</font> tests of     our <font color="blue">goodwill may</font> result in <font color="blue">additional</font> <font color="blue">impairment</font> charges based on these     changing  estimates, <font color="blue">which could</font> have a material adverse effect on our     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> may suffer if <font color="blue">studies conducted by</font> our <font color="blue">Preclinical </font>    Division are delayed or reduced in scope, performed <font color="blue">improperly</font> or terminated     or if contracts are not <font color="blue">priced properly</font></td>
    </tr>
    <tr>
      <td>Our contracts for our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>provide that <font color="blue">services may</font> be     delayed, reduced in scope or <font color="blue">terminated upon written</font> notice</td>
    </tr>
    <tr>
      <td>Terminations,     delays or <font color="blue">reductions may</font> occur for a variety of reasons, including the     failure of products to satisfy safety requirements, unfavorable interim test     results of the study services, lack of <font color="blue">availability</font> of test material, the     customerapstas decision to terminate the <font color="blue">development</font> of a <font color="blue">test compound</font> or to     end a <font color="blue">particular study</font>, and our failure to perform properly our <font color="blue">duties under</font>     the <font color="blue">study services contract</font></td>
    </tr>
    <tr>
      <td>Any delay, reduction in scope or <font color="blue">termination</font> could cause us to be unable to     recover our costs or to realize profit on the <font color="blue">affected contract</font> and could     have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>If a study is <font color="blue">improperly</font>     performed,  we may have to repeat the study at our expense, refund the     customer for the cost of the study and/or provide other remedies</td>
    </tr>
    <tr>
      <td>Under fixed price contracts, there is the risk that we will <font color="blue">improperly</font> price     one or more such contracts, <font color="blue">which could</font> result in our not recovering our     anticipated costs or <font color="blue">profit from such contracts</font></td>
    </tr>
    <tr>
      <td>Under <font color="blue">cost plus contracts</font>     with <font color="blue">United States </font>Government agencies, there is the risk of <font color="blue">disallowance by</font>     <font color="blue">such agencies</font> of <font color="blue">certain costs as</font> a result of specific <font color="blue">regulations</font> and     audits</td>
    </tr>
    <tr>
      <td>Although our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font><font color="blue">contracts may entitle us</font> to     receive <font color="blue">costs through</font> the date of <font color="blue">termination</font> and, in some instances, a     portion of our profit or a <font color="blue">cancellation fee</font>, it may be <font color="blue">difficult</font> to collect     <font color="blue">such amounts from</font> a customer who has decided to terminate a study</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on third parties</font> to <font color="blue">supply us with</font> animals</td>
    </tr>
    <tr>
      <td>For our <font color="blue"><font color="blue">Preclinical </font>Division</font>, we purchase the <font color="blue">animals used</font> for our studies     from  a  number  of  <font color="blue">different</font>  suppliers,  two of which are our major     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We don’t generally have <font color="blue">problems with</font> an <font color="blue">adequate supply</font> of     these animals, although from time to time there can be <font color="blue">temporary shortages</font>     for a particular species due to unanticipated demand, vendor-related events,     <font color="blue">health issues</font> and other factors, <font color="blue">which could</font> lead to delays in commencing     studies or <font color="blue">possible cancellation</font> of studies</td>
    </tr>
    <tr>
      <td>Certain large animals, which     are <font color="blue">necessary</font> to <font color="blue">conduct certain studies</font> and are only available abroad, may     be more <font color="blue">difficult</font> to obtain</td>
    </tr>
    <tr>
      <td>The supply of these animals can be <font color="blue">affected by</font>     <font color="blue">factors beyond</font> our control, including but not limited to, export and import     <font color="blue">regulations</font> and practices, natural disasters, political unrest, disease     outbreaks,  <font color="blue">competition</font> for supply and the limited number of potential     suppliers and sources</td>
    </tr>
    <tr>
      <td>Such <font color="blue">shortages could</font> be of <font color="blue">lengthy duration</font> and could     result in delays or <font color="blue">cancellations</font> of <font color="blue">higher value studies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Preclinical </font>research <font color="blue">services may</font> expose us to <font color="blue">liability</font> and related risks</td>
    </tr>
    <tr>
      <td>To  the extent that our customers develop or use products based on our     studies,  if  studies are not properly performed, we may be exposed to     <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Contractual </font><font color="blue">indemnifications generally</font> do not <font color="blue">protect us against</font>     <font color="blue">liability</font> arising <font color="blue">from certain</font> of our own actions, such as negligence or     <font color="blue">misconduct</font></td>
    </tr>
    <tr>
      <td>We  could be <font color="blue">materially</font> and <font color="blue">adversely</font> affected if we were     required to pay damages or bear the costs of defending any claim which is     not <font color="blue">covered by</font> a <font color="blue">contractual indemnification provision</font> and is outside of or     exceeds  our  <font color="blue">insurance coverage</font> or in the event that a party who must     <font color="blue">indemnify us</font> does not fulfill its indemnification <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>While we     currently maintain <font color="blue">professional</font> <font color="blue">liability</font> insurance, our <font color="blue">insurance coverage</font>     may not be adequate to <font color="blue">protect us against</font> future claims</td>
    </tr>
    <tr>
      <td>Furthermore, our     <font color="blue">customers may</font> not <font color="blue">indemnify us</font> against these types of claims or may not     <font color="blue">themselves</font> be <font color="blue">adequately insured</font> or, in the case of <font color="blue">smaller companies</font>, have     a <font color="blue">net worth sufficient</font> to satisfy any <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>Actions of animal rights <font color="blue">extremists</font> may affect our business</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>requires the use of animals in our <font color="blue">testing studies</font>     of the safety and efficacy of <font color="blue">candidate compounds</font></td>
    </tr>
    <tr>
      <td>Acts of vandalism and     other wrongful acts by animal rights <font color="blue">extremists</font> who object to the use of     animals in drug <font color="blue">development</font> could have a material adverse effect on our     business</td>
    </tr>
    <tr>
      <td>While we have <font color="blue">taken certain <font color="blue">security measures</font></font> to protect our     <font color="blue"><font color="blue"><font color="blue">Preclinical </font>Division</font> </font>employees and <font color="blue">facilities</font>, we <font color="blue">cannot prevent</font> all actions     that may be taken by animal rights <font color="blue">extremists</font></td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________           <font color="blue">Risks Related </font>to Our <font color="blue"><font color="blue"><font color="blue">Drug Repositioning Division</font> </font>    </font>The <font color="blue">development</font> of the <font color="blue">repositioning</font> <font color="blue">technologies</font> for our Drug Repositioning     Division creates risks and <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">technologies</font> that form the foundation of our <font color="blue"><font color="blue"><font color="blue">Drug Repositioning Division</font> </font>    </font>require further <font color="blue">development</font> and such <font color="blue">development</font> could take longer or cost     more than we anticipate</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of the <font color="blue">technologies</font> could prove to     be <font color="blue">less effective than</font> we need in order to offer these services <font color="blue">effectively</font></td>
    </tr>
    <tr>
      <td>Moreover, the mere <font color="blue">development</font> of these <font color="blue">technologies</font> does not assure that     they will, in turn, enable us to be successful in determining potential     <font color="blue">alternative</font> <font color="blue">therapeutic</font> uses for our partners’ drug <font color="blue">candidates</font> or that we     will be able to utilize these <font color="blue">technologies</font> at <font color="blue">capacity</font> levels that will     enable us to achieve our business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>In  addition, these <font color="blue">technologies</font> may rely on inventions to <font color="blue">which third</font>     parties have obtained or are obtaining patent or other rights and we may     need to in-<font color="blue">license rights</font> to <font color="blue">use such inventions</font></td>
    </tr>
    <tr>
      <td>We may not be able to     obtain or retain <font color="blue">license rights</font> needed for one or more of these <font color="blue">technologies</font>     on terms acceptable to us</td>
    </tr>
    <tr>
      <td>In particular, we license certain <font color="blue">technology</font> in     <font color="blue"><font color="blue">connection</font> with certain products purchased from</font> <font color="blue">Xenogen Corporation </font>and we     also  purchase  and  license  the right to use <font color="blue">Luciferase </font>from Promega     Corporation</td>
    </tr>
    <tr>
      <td><font color="blue">The Xenogen </font>license is for a term ending in 2008 with an option     to renew for an <font color="blue">additional</font> three years</td>
    </tr>
    <tr>
      <td><font color="blue">The Promega </font>license is for a period     ending on the expiration or <font color="blue">abandonment</font> of the last of the valid claims of     the <font color="blue">licensed <font color="blue">patent rights</font></font></td>
    </tr>
    <tr>
      <td>Each of these licenses is terminable if we     breach the <font color="blue">agreement</font> and fail to cure such <font color="blue">breach within</font> the applicable cure     period</td>
    </tr>
    <tr>
      <td>In addition, the Promega license includes a sublicense to rights     owned  by  an  <font color="blue">academic institution</font> and the <font color="blue">license from</font> Promega would     terminate  if  the  license  to  Promega from the <font color="blue">academic institution</font>     terminated</td>
    </tr>
    <tr>
      <td>If either of these <font color="blue"><font color="blue">agreement</font>s</font> were to <font color="blue">terminate while</font> the     <font color="blue">relevant patent</font> claims were enforceable and if we were not able to obtain     <font color="blue">new licenses</font>, we would have to abandon or <font color="blue"><font color="blue">substantially</font> revise one</font> of the     key <font color="blue">technologies</font> used in our <font color="blue"><font color="blue">drug <font color="blue">repositioning</font></font> process</font></td>
    </tr>
    <tr>
      <td>Even if we <font color="blue">successfully</font> develop the <font color="blue">repositioning</font> <font color="blue">technologies</font> for our Drug     Repositioning Division, these <font color="blue">technologies</font> may be quickly replaced, thereby     making our <font color="blue">current approach obsolete</font>, or <font color="blue">others may</font> acquire or develop the     same or similar <font color="blue">technologies</font> <font color="blue">which could</font> create <font color="blue">competition</font> for our services     and, ultimately, could cause material risk of <font color="blue">financial losses</font></td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font>companies and other companies and <font color="blue">research <font color="blue">organization</font>s</font> are     developing individual <font color="blue">technologies</font> for better understanding the complex     biological processes <font color="blue">affected by</font> compounds and selecting, purposing and     <font color="blue"><font color="blue">repurposing</font> compounds</font></td>
    </tr>
    <tr>
      <td>Such other parties may elect to use such <font color="blue">technologies</font>     <font color="blue">internally</font>, in lieu of using our services, or may <font color="blue">successfully</font> offer such     <font color="blue">services based on</font> their <font color="blue">technologies</font> in <font color="blue">competition</font> <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>While we     have <font color="blue">license rights</font> related to certain of the <font color="blue">technologies</font> that comprise the     <font color="blue"><font color="blue">technology</font> platform</font> for our <font color="blue">Drug Repositioning Division</font>, we do not currently     have <font color="blue">issued patents</font> to any of the <font color="blue">technologies</font> and our <font color="blue">license rights</font> are     generally non-exclusive</td>
    </tr>
    <tr>
      <td>We <font color="blue">will seek patents</font> or other <font color="blue">protection on</font> other     elements of the <font color="blue">technologies</font> we use to <font color="blue">reposition drug compounds</font></td>
    </tr>
    <tr>
      <td>We may not     be able to obtain <font color="blue">such protection</font> or the <font color="blue">technology</font> <font color="blue">may become obsolete</font></td>
    </tr>
    <tr>
      <td>We  may  be  required  to  <font color="blue">invest <font color="blue">significant</font> resources</font> in identifying     <font color="blue">alternative</font>  uses  for  our partners’ compounds and we may not realize     <font color="blue">significant</font> <font color="blue">revenue from</font> <font color="blue">successfully</font> repositioned drug <font color="blue">candidates</font> based on     our work</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">Drug Repositioning Division</font> </font><font color="blue"><font color="blue">agreement</font>s</font> provide revenue primarily from     success-based milestones and <font color="blue">royalties based on</font> the <font color="blue">successful <font color="blue">repositioning</font></font>     and <font color="blue">commercial sales</font>  of drug <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Typically, we have agreed to     perform  our  <font color="blue"><font color="blue">Drug Repositioning Division</font> </font>assessments without up-front     payments</td>
    </tr>
    <tr>
      <td>Accordingly,  we  may  need to <font color="blue">invest <font color="blue">significant</font> resources</font> in seeking     <font color="blue">alternative</font>  uses  for one or more partners’ drug <font color="blue">candidates</font> using our     <font color="blue">repositioning</font> <font color="blue">technologies</font>, and we <font color="blue">may find no new</font> or <font color="blue">alternative</font> uses for     these  compounds</td>
    </tr>
    <tr>
      <td>If  we identify new or <font color="blue">alternative</font> uses for a given     compound, we may not be able to realize any <font color="blue">value from</font> the <font color="blue">identification</font> of     such <font color="blue">alternative</font> use until our partner determines, if ever, that the use     makes the <font color="blue">compound sufficiently desirable</font> to warrant further <font color="blue">development</font> and     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We do not control when, on what schedule or whether a     <font color="blue">partner will accept</font> a <font color="blue">drug candidate</font> for re<font color="blue">development</font> or at what pace, if     at  all,  the  partner will conduct further <font color="blue">development</font> effort of such     repositioned <font color="blue">drug candidate</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">decisions may</font> be <font color="blue">affected by</font> internal     policies and <font color="blue">organization</font> and other factors of which we may not be aware and     over which we will have no influence</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________           In the event that a partner declined to develop a compound for an <font color="blue">indication</font>     we  had  found,  we  could acquire rights to develop that compound for     particular <font color="blue">indication</font>s and, if we were to elect to pursue <font color="blue">development</font> of any     <font color="blue">such compound</font>, any such <font color="blue">development</font> would require that we <font color="blue">promptly find</font> a     partner and/or that we invest substantial financial and other resources to     develop  the  product  to  a  stage where we <font color="blue">could license</font> it out to a     third-party for final <font color="blue">development</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We have not engaged     in compound <font color="blue">development</font> to date and there can be no assurance that we would     be successful in conducting such <font color="blue">development</font> or in identifying a licensing     partner to continue such <font color="blue">development</font> on terms that would be profitable to     us</td>
    </tr>
    <tr>
      <td>These <font color="blue">factors may limit</font> our ability to <font color="blue">earn <font color="blue">significant</font> revenue under</font> any of     our <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our approach to <font color="blue"><font color="blue">drug <font color="blue">repositioning</font></font> may</font> not yield sufficient new <font color="blue">indication</font>s     and <font color="blue"><font color="blue">thus measurable success</font>es</font> to gain wide-spread market acceptance</td>
    </tr>
    <tr>
      <td>We may not succeed in achieving <font color="blue"><font color="blue">significant</font> commercial market acceptance</font> of     any of our <font color="blue">technologies</font> used in <font color="blue"><font color="blue">drug <font color="blue">repositioning</font></font> <font color="blue">activities</font></font> because the     <font color="blue">technologies</font> we use and our approach to <font color="blue"><font color="blue">drug <font color="blue">repositioning</font></font> may</font> fail to     generate sufficient new <font color="blue">indication</font>s and <font color="blue">thus measurable success</font> for our     <font color="blue">pharmaceutical</font> partners</td>
    </tr>
    <tr>
      <td>This <font color="blue">outcome would</font> have a material adverse effect     on our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and market     valuation</td>
    </tr>
    <tr>
      <td>The <font color="blue">sales cycle</font> for our <font color="blue"><font color="blue">Drug Repositioning Division</font> </font>is lengthy; we may spend     considerable <font color="blue">resources on unsuccessful <font color="blue">sales efforts</font></font> or may not be able to     complete <font color="blue">deals on</font> the schedule we anticipate</td>
    </tr>
    <tr>
      <td>Our  Drug  Repositioning Division <font color="blue">strategy depends</font> upon our ability to     establish  <font color="blue">collaborative arrangements with</font>  <font color="blue">pharmaceutical</font> partners to     repurpose  current  clinical  failures in their pipelines</td>
    </tr>
    <tr>
      <td>If our Drug     Repositioning Division is unable to <font color="blue">establish <font color="blue">partnerships</font> with sufficient</font>     <font color="blue">additional</font> <font color="blue">pharmaceutical</font> companies, we may not be able to obtain enough     compounds for <font color="blue">repurposing</font> and, ultimately, to recoup the <font color="blue">investment</font> we will     have made in the <font color="blue">development</font> of this business</td>
    </tr>
    <tr>
      <td>Our ability to obtain <font color="blue">new customers</font> depends upon our ability to convince     them  that our <font color="blue"><font color="blue">drug <font color="blue">repositioning</font></font> approach</font> and <font color="blue"><font color="blue">technology</font> platform</font> can     <font color="blue">increase productivity</font> for their drug <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>The <font color="blue">sales cycle</font>     for our <font color="blue"><font color="blue">Drug Repositioning Division</font> </font><font color="blue">partnerships</font> can take up to 12 months,     and in certain <font color="blue">circumstances</font> longer, to complete</td>
    </tr>
    <tr>
      <td>The lengthy <font color="blue">sales cycle</font> is     caused by a number of factors, including our need to <font color="blue">educate potential</font>     <font color="blue">customers on</font> the benefits of our approach to <font color="blue">drug <font color="blue">repositioning</font></font> and the     <font color="blue">technologies</font> we use</td>
    </tr>
    <tr>
      <td>In addition, each <font color="blue">agreement</font> may involve the <font color="blue">negotiation</font>     of  terms  in  a  context  not familiar to our partners</td>
    </tr>
    <tr>
      <td>We may expend     substantial <font color="blue">effort with no assurance</font> that a new <font color="blue">agreement</font> will result</td>
    </tr>
    <tr>
      <td>Actual and proposed <font color="blue">consolidations</font> of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     companies <font color="blue">could affect</font> the timing and progress of our Drug Repositioning     Division <font color="blue">sales efforts</font></td>
    </tr>
    <tr>
      <td>Furthermore, we may not be able to convince other customers to <font color="blue">enter into</font>     <font color="blue"><font color="blue">agreement</font>s</font> for services or on terms that are acceptable to us</td>
    </tr>
    <tr>
      <td>We  have  incurred  operating losses in <font color="blue">each year since</font> our inception,     including losses of dlra48dtta3 million in 2005, dlra28dtta5 million in 2004 and dlra24dtta8     million in 2003</td>
    </tr>
    <tr>
      <td>At <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of     dlra261dtta0 million</td>
    </tr>
    <tr>
      <td>Our losses have resulted <font color="blue">principally from costs incurred</font> in     the  <font color="blue">development</font>, marketing and sale of <font color="blue">services from</font> our Genomics and     <font color="blue"><font color="blue">Preclinical </font>Division</font>s, <font color="blue">development</font> of the <font color="blue">Drug Repositioning Division</font>, the     <font color="blue">impairment</font> of goodwill described herein, and <font color="blue">acquisition</font>s of research and     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>These costs have exceeded our revenue and we expect to incur     <font color="blue">additional</font> losses in the future, including substantial losses relating to     the ongoing <font color="blue">development</font> costs of our <font color="blue">Drug Repositioning Division</font></td>
    </tr>
    <tr>
      <td>Our revenue is <font color="blue">derived primarily from</font>, and is subject to <font color="blue">risks faced by</font>, the     <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> <font color="blue">industries</font> in the United States, Japan,     Europe and other foreign countries; our revenue is also subject to foreign     <font color="blue">currency risk</font></td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________           We  expect that our revenue <font color="blue">will continue</font> to be <font color="blue">derived primarily from</font>     <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with</font> <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font> companies, as well as     United  States  Government  agencies</td>
    </tr>
    <tr>
      <td>As a consequence, our results of     <font color="blue">operations</font> may fluctuate <font color="blue">substantially</font> due to <font color="blue">fluctuations</font> or delays in our     customers’ research and <font color="blue">development</font> <font color="blue">expenditures</font> and other <font color="blue">factors affecting</font>     their <font color="blue">purchasing decisions</font></td>
    </tr>
    <tr>
      <td>These factors include:         ·       <font color="blue">fluctuations</font> in current or <font color="blue">potential customers</font>’ research and <font color="blue">development</font>     budgets;         ·       changes in national or <font color="blue">international economic <font color="blue">conditions</font></font>;         ·       access to <font color="blue">capital markets by current</font> or potential <font color="blue">bio<font color="blue">technology</font></font> customers;         ·       market-driven pressures on current or <font color="blue">potential customers</font> to improve     productivity efficiencies through consolidation, cost reduction and overall     research and <font color="blue">development</font> effectiveness;                   ·           <font color="blue">decisions by current</font> or <font color="blue">potential customers</font> to purchase new, improved and/or     <font color="blue">alternative</font> <font color="blue">technologies</font>;         ·       pressure to limit <font color="blue">government</font> spending in <font color="blue">sectors relevant</font> to our business or     changes in <font color="blue">government</font> procurement practices, including the process for     determining <font color="blue">reimbursement rates</font> related to <font color="blue">United States </font>Government     contracts;           ·       mergers and <font color="blue">acquisition</font>s within the <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>     industry resulting in fewer <font color="blue">potential customers</font> for our services and     solutions;           ·       new or more <font color="blue">stringent application</font> of FDA and other laws and <font color="blue">regulations</font> in     the <font color="blue">drug approval process</font>; and         ·       <font color="blue">regulatory</font> reviews by the FDA or other <font color="blue">regulatory</font> bodies that <font color="blue">could delay</font> or     increase costs <font color="blue">associated with</font> drug <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In addition, beginning in 2005, contracts with our Japanese customers are     payable in  <font color="blue">Japanese Yen </font>and are subject to <font color="blue">fluctuations</font> due to changes in     currency exchange rates</td>
    </tr>
    <tr>
      <td>Certain <font color="blue">investment</font>s made by the Company may fluctuate in value and may     create an <font color="blue">adverse impact on</font> our financial performance; the value of certain     of our <font color="blue">intangibles</font> and long-term <font color="blue">investment</font>s creates risk to our financial     performance</td>
    </tr>
    <tr>
      <td>We’ve <font color="blue">previously recorded value</font> for goodwill and other <font color="blue">intangible assets</font>,     including  licenses to <font color="blue">technologies</font> or data, patent costs and software     <font color="blue">development</font> and database upgrade costs which, at <font color="blue">December </font>31, 2005, had an     <font color="blue">aggregate value</font> of dlra26dtta3 million</td>
    </tr>
    <tr>
      <td>Whether or not these <font color="blue">intangible assets</font> are     impaired involves <font color="blue">significant</font> judgment, including the following: (i) whether     our licenses and <font color="blue">internally</font> developed <font color="blue">intellectual</font> property may not provide     valid and economical <font color="blue">competitive</font> advantage; and (ii) whether our services we     provide  may  become  obsolete before we recover the costs incurred in     <font color="blue">connection</font> with their <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Under Statement of Financial Accounting     Standards Nodtta 142, “Goodwill and Other Intangible Assets”, we are required     to perform <font color="blue">periodic reviews</font> of our <font color="blue">intangible assets</font> and we may be required     to reduce the value of these assets if <font color="blue">circumstances</font> change</td>
    </tr>
    <tr>
      <td>In addition, we have an <font color="blue">investment</font> in MetriGenix, Inc</td>
    </tr>
    <tr>
      <td>with a <font color="blue">book value as</font>     of <font color="blue">December </font>31, 2005 of dlra3dtta2 million</td>
    </tr>
    <tr>
      <td>This <font color="blue">investment</font> is subject to periodic     <font color="blue">evaluation</font> for <font color="blue">impairment</font></td>
    </tr>
    <tr>
      <td>Since MetriGenix is an <font color="blue">independent company</font> in     which we are a <font color="blue">minority stockholder</font>, the <font color="blue">factors affecting</font> an <font color="blue">impairment</font>     analysis, which include potential revenue, cost of capital and <font color="blue">fair market</font>     value  of  the  entity, is not within our control</td>
    </tr>
    <tr>
      <td>In the future, this     <font color="blue">investment</font> may require an <font color="blue">impairment</font> charge in the future</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">adequate patent protection</font> for new <font color="blue">technologies</font>     and methods required for achieving our business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to <font color="blue">protect <font color="blue">confidential</font></font>     information  and  to  obtain <font color="blue">intellectual</font> property rights and licenses     sufficient to <font color="blue">provide adequate <font color="blue">exclusivity</font></font> and to preserve our freedom to     operate</td>
    </tr>
    <tr>
      <td>We rely on <font color="blue"><font color="blue">confidential</font>ity</font> <font color="blue"><font color="blue">agreement</font>s</font> and other <font color="blue">trade secret protective</font>     measures to protect our interests in <font color="blue">proprietary</font> know-how and <font color="blue">technology</font>     that are not patentable or for <font color="blue">which patents</font> are <font color="blue">difficult</font> to enforce</td>
    </tr>
    <tr>
      <td>We     have  taken  <font color="blue">security measures</font> to protect our <font color="blue">proprietary</font> know-how and     <font color="blue"><font color="blue">confidential</font> data</font> and continue to <font color="blue">explore further methods</font> of protection</td>
    </tr>
    <tr>
      <td>While we require all employees, consultants and <font color="blue">customers with access</font> to our     <font color="blue">trade secrets</font> to <font color="blue">enter into</font> <font color="blue"><font color="blue">confidential</font>ity</font> <font color="blue"><font color="blue">agreement</font>s</font>, we cannot be certain     that  we  will  be  able to protect our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely on</font>     <font color="blue"><font color="blue">confidential</font>ity</font>  procedures to <font color="blue">prevent public disclosure</font> of patentable     <font color="blue">proprietary</font>  <font color="blue">technology</font>  prior to <font color="blue">filing patents</font></td>
    </tr>
    <tr>
      <td>Any material leak of     <font color="blue">confidential</font> information into the <font color="blue">public domain</font>, or to third parties, could     cause our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> to suffer     <font color="blue">adverse consequences</font>, including <font color="blue">possible loss</font> of <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent position involves complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td><font color="blue">Legal     </font>standards relating to the validity and scope of claims in the genomics     <font color="blue">technology</font> field are <font color="blue">still evolving</font></td>
    </tr>
    <tr>
      <td>Therefore, the degree of <font color="blue">exclusivity</font>     that future patent protection may provide for our <font color="blue">proprietary</font> <font color="blue">technologies</font>     in this field is uncertain</td>
    </tr>
    <tr>
      <td>Likewise, <font color="blue">legal standards</font> relating to validity     of claims to new methods of <font color="blue">using known drugs</font> are <font color="blue">still evolving</font></td>
    </tr>
    <tr>
      <td>Hence, the     likelihood of patenting potential new <font color="blue">therapeutic</font> uses of <font color="blue">drug <font color="blue">repositioning</font></font>     <font color="blue">candidates</font> also is uncertain</td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________       <font color="blue">Specific  </font>risks  and  <font color="blue">uncertainties</font> that we face in the area of patent     <font color="blue">exclusivity</font> include:         ·       the <font color="blue">pending <font color="blue">patent applications</font></font> we have filed, or to which we have licensed     rights, may not result in <font color="blue">issued patents</font> or may take <font color="blue">longer than</font> we expect     to result in <font color="blue">issued patents</font>;             ·           the claims of any <font color="blue">patents which</font> are issued on our <font color="blue">pending applications may</font>     not <font color="blue">provide commercially meaningful protection</font> or value;         ·       the <font color="blue">patents licensed</font> or issued to us may not <font color="blue">provide adequate <font color="blue">exclusivity</font></font>     for all aspects of our <font color="blue">proprietary</font> genomics <font color="blue">technology</font>;         ·       other <font color="blue">companies may challenge <font color="blue">patents issued</font></font> or licensed to us; and         ·       we may not be able to obtain <font color="blue">adequate patent protection</font> for     <font color="blue">commercialization</font> of a <font color="blue">potential new use</font> of a <font color="blue">successfully</font> repositioned drug     candidate</td>
    </tr>
    <tr>
      <td>We may need to <font color="blue">initiate patent enforcement <font color="blue">litigation</font></font> or be subject to     <font color="blue">future infringement</font> claims</td>
    </tr>
    <tr>
      <td>In  addition,  other  <font color="blue">organization</font>s, including companies, academic and     non-profit  <font color="blue">institutions</font> and <font color="blue">government</font>al <font color="blue">organization</font>s are developing     <font color="blue">technologies</font> in the genomics and <font color="blue">drug <font color="blue">repositioning</font></font> fields</td>
    </tr>
    <tr>
      <td>Many of these     <font color="blue">technologies</font> are subject to the same evolving <font color="blue">legal standards</font> and related     <font color="blue">uncertainties</font> about patent protection as our <font color="blue">proprietary</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Therefore, it may be <font color="blue">necessary</font> for us to <font color="blue">initiate <font color="blue">litigation</font></font> to protect and     enforce our <font color="blue">intellectual</font> property rights</td>
    </tr>
    <tr>
      <td>We <font color="blue">also face risks</font> that <font color="blue">patents issued</font> to other <font color="blue">organization</font>s may restrict     our ability to do business, and that we may be unable to obtain or maintain     licenses  providing  freedom to operate on acceptable terms</td>
    </tr>
    <tr>
      <td>Thus, the     <font color="blue">technologies</font>  that  we  use to develop our services, and those that we     incorporate in our services, may be subject to claims that they infringe the     patents or <font color="blue">proprietary</font> rights of others</td>
    </tr>
    <tr>
      <td>In particular, we are aware of a     number  of patents and <font color="blue">patent applications</font> owned by others relating to     <font color="blue">genetic markers</font> and to the analysis of <font color="blue">gene expression</font> or the <font color="blue">manufacture</font>     and use of <font color="blue">microarray</font>s and related materials</td>
    </tr>
    <tr>
      <td>Therefore, we could be sued by     parties alleging <font color="blue">patent infringement</font></td>
    </tr>
    <tr>
      <td>The risk of involvement in <font color="blue">patent <font color="blue">litigation</font> may increase as</font> the genomics,     <font color="blue">bio<font color="blue">technology</font></font> and software <font color="blue">industries</font> and <font color="blue">drug <font color="blue">repositioning</font></font> businesses     expand,  more patents are issued and other <font color="blue">organization</font>s engage in our     business fields</td>
    </tr>
    <tr>
      <td>We <font color="blue">could incur</font> substantial <font color="blue"><font color="blue">litigation</font> costs</font> to defend     ourselves  in <font color="blue">patent infringement</font> suits brought by other parties or to     <font color="blue">initiate such suits</font></td>
    </tr>
    <tr>
      <td>In addition, patent <font color="blue">litigation</font> could cause <font color="blue">disruption</font>     in our business <font color="blue">activities</font> and divert <font color="blue">management</font>’s time and <font color="blue">attention from</font>     the operation of our business</td>
    </tr>
    <tr>
      <td>In that regard, we have in the <font color="blue">past purchased</font>     reagents from <font color="blue"><font color="blue">Affymetrix</font> </font>made by Enzo, and we also purchased such reagents     directly from Enzo</td>
    </tr>
    <tr>
      <td>In late 2003, Enzo terminated the <font color="blue">agreement</font> under which     <font color="blue"><font color="blue">Affymetrix</font> </font><font color="blue">distributed</font> that reagent and <font color="blue">filed suit against</font> <font color="blue">Affymetrix</font></td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Affymetrix</font> </font> <font color="blue">subsequently</font>  filed  a <font color="blue">counter suit</font> and the two suits were     <font color="blue">consolidated</font></td>
    </tr>
    <tr>
      <td>In those suits, Enzo alleges, among other things, rights to     certain <font color="blue"><font color="blue">Affymetrix</font> </font><font color="blue">technologies</font> and that <font color="blue"><font color="blue">Affymetrix</font> </font>had <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with</font> Gene     Logic and other <font color="blue">named customers</font> to supply the reagent for use in potential     violation of their rights</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Affymetrix</font> </font>has denied Enzo’s claims and made its     own <font color="blue">counterclaims</font></td>
    </tr>
    <tr>
      <td>We have not been made a party to that suit; we cannot     predict the outcome of this <font color="blue">litigation</font>, its effect on us or the potential,     if any, for claims being made <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">commenced using</font> a new     <font color="blue"><font color="blue">Affymetrix</font> </font> <font color="blue">reagent kit</font></td>
    </tr>
    <tr>
      <td>Although we have had <font color="blue">discussions with</font> Enzo to     attempt to resolve any claims Enzo believes it may have <font color="blue">with respect</font> to our     use of Enzo’s reagent, we have not reached any <font color="blue">agreement</font> as of the date of     this Form 10-K       Our  <font color="blue">activities</font>  involve  <font color="blue">hazardous</font>  materials  and  may subject us to     <font color="blue">environment</font>al <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>Certain <font color="blue">activities</font> of our <font color="blue">businesses involve</font> the <font color="blue">controlled use</font> of limited     quantities  of  <font color="blue">hazardous</font>  and  <font color="blue">radioactive materials</font> and may generate     biological  waste</td>
    </tr>
    <tr>
      <td>We are subject to federal, state and <font color="blue">local laws</font> and     <font color="blue">regulations</font> governing the use, <font color="blue">manufacture</font>, storage, handling and disposal     of these materials and <font color="blue">certain waste products</font></td>
    </tr>
    <tr>
      <td>Although we believe that our     <font color="blue">safety procedures</font> for handling and disposing of these materials <font color="blue">comply with</font>     <font color="blue">prescribed standards</font>, we <font color="blue">cannot completely eliminate</font> the risk of <font color="blue"><font color="blue">accident</font>al</font>     <font color="blue">contamination</font> or <font color="blue">injury from</font> these materials</td>
    </tr>
    <tr>
      <td>In the event of an <font color="blue">accident</font> or     we <font color="blue">otherwise fail</font> to <font color="blue">comply with</font> applicable <font color="blue">regulations</font>, we <font color="blue">could lose</font> our     permits and/or approvals or be held liable for damages or <font color="blue">penalized with</font>     fines</td>
    </tr>
    <tr>
      <td>We believe that we comply in all material <font color="blue">respects with currently applicable</font>     <font color="blue">environment</font>al laws and <font color="blue">regulations</font> and do not expect near term material     <font color="blue">additional</font>  capital <font color="blue">expenditures</font> for <font color="blue">environment</font>al control <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>However, we may have to incur <font color="blue">significant</font> costs in the future to <font color="blue">comply with</font>     <font color="blue">environment</font>al laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">stock price could</font> be volatile and <font color="blue">could decline</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> for securities of <font color="blue">bio<font color="blue">technology</font></font> and other <font color="blue">technology</font>     companies  serving  the  healthcare  industry have <font color="blue">been volatile</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">volatility</font> has <font color="blue">significant</font>ly affected the <font color="blue"><font color="blue">market price</font>s</font> for these securities     for  reasons  <font color="blue">frequently unrelated</font> to the operating performance of the     <font color="blue">specific companies</font></td>
    </tr>
    <tr>
      <td>These broad market <font color="blue">fluctuations</font> may <font color="blue">adversely</font> affect the     market  price  of  our <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>Events or factors that may have a     <font color="blue">significant</font> impact on our business and on the <font color="blue">market price</font> of our Common     Stock include those in the <font color="blue">Risk Factors </font>set forth in this section and the     following:         ·       slowing of <font color="blue">revenue growth</font> in our base business;         ·       quarterly and <font color="blue">annual financial</font> and operating results;         ·       failure to meet estimates or <font color="blue">expectations</font> of <font color="blue">securities analysts</font> or our     <font color="blue">projections</font>;         ·       sales and/or purchases of our <font color="blue">Common Stock</font> by members of our senior     <font color="blue">management</font> and Board of Directors;         ·       <font color="blue">announcements</font> by us or others of <font color="blue">technological innovations</font> or <font color="blue">new products</font>     or <font color="blue">announcements</font> regarding our services and solutions;         ·       <font color="blue">development</font>s in patent or other <font color="blue">proprietary</font> rights;         ·       the loss of <font color="blue">significant</font> licenses or supply <font color="blue"><font color="blue">agreement</font>s</font>;         ·       <font color="blue">future sales</font> of substantial amounts of our <font color="blue">Common Stock</font> by our existing     <font color="blue">stockholders</font>;         ·       changing <font color="blue">market perception</font> regarding <font color="blue">investment</font>s in the <font color="blue">pharmaceutical</font> and     <font color="blue">bio<font color="blue">technology</font></font> <font color="blue">industries</font>;         ·       results of <font color="blue">clinical trials</font> of potential repurposed drug <font color="blue">candidates</font> resulting     from our <font color="blue">Drug Repositioning Division</font>; and         ·       general market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>These and other <font color="blue">external factors may</font> cause the <font color="blue">market price</font> and demand for     our <font color="blue">Common Stock</font> to fluctuate <font color="blue">substantially</font>, which may limit or prevent     investors  from  readily  selling their shares of <font color="blue">Common Stock</font> and may     otherwise <font color="blue">negatively</font> affect the liquidity of our <font color="blue">Common Stock</font></td>
    </tr>
  </tbody>
</table>